Stock Price Prediction

OMER

0.000

0.000(0.000%)

OMER Similar Chart Price Prediction

The price of OMER is predicted to go up -2.01%, based on the high correlation periods with DXR. The similarity of these two price pattern on the periods is 93.18%.

OMER

DXR

Down: -2.01%Similarity: 93.18%

OMER Revenue Forecast

OMER EPS Forecast

OMER VS S&P500

Ask Intellectia about OMER

OMER Analyst's Forecast

Jason Kolbert

D. Boral Capital

Strong Buy

2024-12-23

Price Target

$36

Upside

+256.08%

D. Boral Capital initiated coverage of Omeros with a Buy rating and $36 price target. With Narsoplimab now poised for U.S. approval, followed by Europe, Omeros is "at an inflection point," argues the analyst, who sees the upcoming resubmission of Narsoplimab's Biologics License Application for thrombotic microangiopathy associated with transplantation as "just the beginning of Omeros' transition to a fully integrated ethical pharma company." FDA approval will make Narsoplimab the first and only approved treatment for TA-TMA, notes the firm, which also believes "strongly in the other products in the company's pipeline," but bases its valuation only on Narsoplimab.

Brandon Folkes

Rodman & Renshaw